The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Prospects for productivity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
A Comparison of Physiochemical Property Profiles of Development and Marketed Oral Drugs
Wenlock, M. C., Austin, R. P., Barton, P., Davis, A. M., & Leeson, P. D. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm021053p · Cited by 546
Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs
Vieth, M., Siegel, M. G., Higgs, R. E., Watson, I. A., Robertson, D. H., Savin, K. A., Durst, G. L., & Hipskind, P. A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030267j · Cited by 359
Horrobin, D. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1012 · Cited by 248
Ma, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Self-citationInnovation in the pharmaceutical industry
Horrobin, D. F. (2000) · Journal of the Royal Society of Medicine · doi:10.1177/014107680009300702 · Cited by 173
Vogel, R. J. (1983) · Social Science & Medicine · doi:10.1016/0277-9536(83)90205-8 · Cited by 161
Drug prototypes and their exploitation
(1997) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(97)84366-8 · Cited by 147
Cited by
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Escape from Flatland 2: complexity and promiscuity
Lovering, F. (2013) · MedChemComm · doi:10.1039/c2md20347b · Cited by 1,444
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Drug–target interaction prediction: databases, web servers and computational models
Chen, X., Yan, C. C., Zhang, X., Zhang, X., Dai, F., Yin, J., & Zhang, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv066 · Cited by 658
Target profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
A survey of current trends in computational drug repositioning
Li, J., Zheng, S., Chen, B., Butte, A. J., Swamidass, S. J., & Lu, Z. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbv020 · Cited by 555
Exploiting drug-disease relationships for computational drug repositioning
Dudley, J. T., Deshpande, T., & Butte, A. J. (2011) · Briefings in Bioinformatics · doi:10.1093/bib/bbr013 · Cited by 524
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Specific chemotherapy of Chagas disease: Relevance, current limitations and new approaches
Urbina, J. A. (2010) · Acta Tropica · doi:10.1016/j.actatropica.2009.10.023 · Cited by 473
Financial Anatomy of Biomedical Research
Moses, H., Dorsey, E. R., Matheson, D. H. M., & Thier, S. O. (2005) · JAMA · doi:10.1001/jama.294.11.1333 · Cited by 447
What Do Medicinal Chemists Actually Make? A 50-Year Retrospective
Walters, W. P., Green, J., Weiss, J. R., & Murcko, M. A. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200504p · Cited by 387
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
Targeting Breast Cancer Stem Cells
Liu, S., & Wicha, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 356
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 336
A review of computational drug repurposing
Park, K. (2019) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2019.27.2.59 · Cited by 300
When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis
Scannell, J. W., & Bosley, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0147215 · Cited by 279
Allosteric modulation of G protein-coupled receptors: A pharmacological perspective
Keov, P., Sexton, P. M., & Christopoulos, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.010 · Cited by 265
Life cycle of translational research for medical interventions
Contopoulos-Ioannidis, D. G., Alexiou, G. A., Gouvias, T. C., & Ioannidis, J. P. A. (2008) · Science · doi:10.1126/science.1160622 · Cited by 207
Novel Methods and Technologies for 21st-Century Clinical Trials: A Review
Dorsey, E. R., Venuto, C., Venkataraman, V., Harris, D. A., & Kieburtz, K. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4524 · Cited by 118
Rodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Expression profiling of drug response - from genes to pathways
Herwig, R., & Lehrach, H. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.3/rherwig · Cited by 14
Metadata
- Authors
- Booth, B., & Zemmel, R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-05
- Volume
- 3
- Issue
- 5
- Pages
- 451-456
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1541232310
- Cited by
- 278
- References
- 12
- FWCI
- 37.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.